Skip to content
Brand AI

Tagrisso

Request correction

Product brand

UnclaimedRead 2× by AI crawlers

Tagrisso is a pharmaceutical product whose official website addresses treatment for certain types of EGFR+ NSCLC.

Last updated September 11, 2026

AI crawler reads

2requests

1companies
  • Anthropic2
Profile
2
Controversies
0
JSON · MD
0
First read
Nov 4, 2026
Latest read
Nov 4, 2026

From this site's server log

Overview

Tagrisso is described in the supplied evidence as a pharmaceutical product. Its official website presents information organized around EGFR+ NSCLC across early-stage disease after surgery, locally advanced unresectable (stage 3) disease, and late-stage disease, and includes sections on clinical trial results, dosing, safety considerations, and support resources.

Recent events

  • Reported

    FDA approves Tagrisso for adjuvant NSCLC therapy[6]

    The FDA approved osimertinib (Tagrisso, AstraZeneca) as adjuvant therapy for patients with non-small cell lung cancer with EGFR mutations. The new indication covers patients with specified EGFR mutations after tumor resection.

Read more

Sources6 sources

  1. 1Treatment for Certain Types of EGFR+ NSCLC | TAGRISSOtagrisso.com
  2. 2Treatment for Early-Stage EGFR+ NSCLC | TAGRISSOtagrisso.com
  3. 3Late-Stage EGFR+ NSCLC | About TAGRISSO®tagrisso.com
  4. 4Targeted Therapies for EGFR+ NSCLC | TAGRISSOtagrisso.com
  5. 5Tagrissowikidata.org
  6. 6FDA 批准 Tagrisso 用于非小细胞肺癌辅助治疗healio.com

Cite this profile: Cite the canonical profile. /brand-wiki/tagrisso · Editorial policy · How profiles are compiled